Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins

Giuseppina Di Mario, Ester Sciaraffia, Marzia Facchini, Francesco Gubinelli, Elisa Soprana, Maddalena Panigada, Valentina Bernasconi, Bruno Garulli, Antonio Siccardi, Isabella Donatelli, Maria R. Castrucci

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The emergence of novel strains of influenza A viruses with hemagglutinins (HAs) that are antigenically distinct from those circulating in humans, and thus have pandemic potential, pose concerns and call for the development of more broadly protective influenza vaccines. In the present study, modified vaccinia virus Ankara (MVA) encoding internal influenza antigens were evaluated for their immunogenicity and ability to protect HLA-A2.1 transgenic (AAD) mice from infection with influenza viruses. Methods: MVAs expressing NP (MVA-NP), M1 (MVA-M1) or polymerase PB1 (MVA-PB1) of A/California/4/09 (CA/09) virus were generated and used to immunize AAD mice. Antibodies and CD8+T cell responses were assessed by ELISA and ELISPOT, respectively, and challenge experiments were performed by infecting vaccinated mice with CA/09 virus. Results: CD8+T cells specific to immunodominant and subdominant epitopes on the internal influenza proteins were elicited by MVA-based vectors in AAD mice, whereas influenza-specific antibodies were detected only in MVA-NP-immunized mice. Both M1- and NP-based MVA vaccines, regardless of whether they were applied individually or in combination, conferred protection against lethal influenza virus challenge. Conclusion: Our data further emphasize the promising potential of MVA vector expressing internal antigens toward the development of a universal influenza vaccine.

Original languageEnglish
Pages (from-to)76-82
Number of pages7
JournalPathogens and Global Health
Volume111
Issue number2
DOIs
Publication statusPublished - Feb 17 2017

Fingerprint

HLA-A2 Antigen
Vaccinia virus
Human Influenza
Transgenic Mice
Immunity
Vaccines
Proteins
Influenza Vaccines
Orthomyxoviridae
Viruses
T-Lymphocytes
Enzyme-Linked Immunospot Assay
Antigens
Immunodominant Epitopes
Antibodies
Influenza A virus
Hemagglutinins
Pandemics
Enzyme-Linked Immunosorbent Assay
Infection

Keywords

  • Influenza virus
  • internal proteins
  • MVA vector
  • transgenic mice
  • vaccine

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins. / Di Mario, Giuseppina; Sciaraffia, Ester; Facchini, Marzia; Gubinelli, Francesco; Soprana, Elisa; Panigada, Maddalena; Bernasconi, Valentina; Garulli, Bruno; Siccardi, Antonio; Donatelli, Isabella; Castrucci, Maria R.

In: Pathogens and Global Health, Vol. 111, No. 2, 17.02.2017, p. 76-82.

Research output: Contribution to journalArticle

Di Mario, Giuseppina ; Sciaraffia, Ester ; Facchini, Marzia ; Gubinelli, Francesco ; Soprana, Elisa ; Panigada, Maddalena ; Bernasconi, Valentina ; Garulli, Bruno ; Siccardi, Antonio ; Donatelli, Isabella ; Castrucci, Maria R. / Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins. In: Pathogens and Global Health. 2017 ; Vol. 111, No. 2. pp. 76-82.
@article{7a61f0983cb54b838524fa09f5a647b6,
title = "Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins",
abstract = "Background: The emergence of novel strains of influenza A viruses with hemagglutinins (HAs) that are antigenically distinct from those circulating in humans, and thus have pandemic potential, pose concerns and call for the development of more broadly protective influenza vaccines. In the present study, modified vaccinia virus Ankara (MVA) encoding internal influenza antigens were evaluated for their immunogenicity and ability to protect HLA-A2.1 transgenic (AAD) mice from infection with influenza viruses. Methods: MVAs expressing NP (MVA-NP), M1 (MVA-M1) or polymerase PB1 (MVA-PB1) of A/California/4/09 (CA/09) virus were generated and used to immunize AAD mice. Antibodies and CD8+T cell responses were assessed by ELISA and ELISPOT, respectively, and challenge experiments were performed by infecting vaccinated mice with CA/09 virus. Results: CD8+T cells specific to immunodominant and subdominant epitopes on the internal influenza proteins were elicited by MVA-based vectors in AAD mice, whereas influenza-specific antibodies were detected only in MVA-NP-immunized mice. Both M1- and NP-based MVA vaccines, regardless of whether they were applied individually or in combination, conferred protection against lethal influenza virus challenge. Conclusion: Our data further emphasize the promising potential of MVA vector expressing internal antigens toward the development of a universal influenza vaccine.",
keywords = "Influenza virus, internal proteins, MVA vector, transgenic mice, vaccine",
author = "{Di Mario}, Giuseppina and Ester Sciaraffia and Marzia Facchini and Francesco Gubinelli and Elisa Soprana and Maddalena Panigada and Valentina Bernasconi and Bruno Garulli and Antonio Siccardi and Isabella Donatelli and Castrucci, {Maria R.}",
year = "2017",
month = "2",
day = "17",
doi = "10.1080/20477724.2016.1275465",
language = "English",
volume = "111",
pages = "76--82",
journal = "Pathogens and Global Health",
issn = "2047-7724",
publisher = "Maney Publishing",
number = "2",

}

TY - JOUR

T1 - Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins

AU - Di Mario, Giuseppina

AU - Sciaraffia, Ester

AU - Facchini, Marzia

AU - Gubinelli, Francesco

AU - Soprana, Elisa

AU - Panigada, Maddalena

AU - Bernasconi, Valentina

AU - Garulli, Bruno

AU - Siccardi, Antonio

AU - Donatelli, Isabella

AU - Castrucci, Maria R.

PY - 2017/2/17

Y1 - 2017/2/17

N2 - Background: The emergence of novel strains of influenza A viruses with hemagglutinins (HAs) that are antigenically distinct from those circulating in humans, and thus have pandemic potential, pose concerns and call for the development of more broadly protective influenza vaccines. In the present study, modified vaccinia virus Ankara (MVA) encoding internal influenza antigens were evaluated for their immunogenicity and ability to protect HLA-A2.1 transgenic (AAD) mice from infection with influenza viruses. Methods: MVAs expressing NP (MVA-NP), M1 (MVA-M1) or polymerase PB1 (MVA-PB1) of A/California/4/09 (CA/09) virus were generated and used to immunize AAD mice. Antibodies and CD8+T cell responses were assessed by ELISA and ELISPOT, respectively, and challenge experiments were performed by infecting vaccinated mice with CA/09 virus. Results: CD8+T cells specific to immunodominant and subdominant epitopes on the internal influenza proteins were elicited by MVA-based vectors in AAD mice, whereas influenza-specific antibodies were detected only in MVA-NP-immunized mice. Both M1- and NP-based MVA vaccines, regardless of whether they were applied individually or in combination, conferred protection against lethal influenza virus challenge. Conclusion: Our data further emphasize the promising potential of MVA vector expressing internal antigens toward the development of a universal influenza vaccine.

AB - Background: The emergence of novel strains of influenza A viruses with hemagglutinins (HAs) that are antigenically distinct from those circulating in humans, and thus have pandemic potential, pose concerns and call for the development of more broadly protective influenza vaccines. In the present study, modified vaccinia virus Ankara (MVA) encoding internal influenza antigens were evaluated for their immunogenicity and ability to protect HLA-A2.1 transgenic (AAD) mice from infection with influenza viruses. Methods: MVAs expressing NP (MVA-NP), M1 (MVA-M1) or polymerase PB1 (MVA-PB1) of A/California/4/09 (CA/09) virus were generated and used to immunize AAD mice. Antibodies and CD8+T cell responses were assessed by ELISA and ELISPOT, respectively, and challenge experiments were performed by infecting vaccinated mice with CA/09 virus. Results: CD8+T cells specific to immunodominant and subdominant epitopes on the internal influenza proteins were elicited by MVA-based vectors in AAD mice, whereas influenza-specific antibodies were detected only in MVA-NP-immunized mice. Both M1- and NP-based MVA vaccines, regardless of whether they were applied individually or in combination, conferred protection against lethal influenza virus challenge. Conclusion: Our data further emphasize the promising potential of MVA vector expressing internal antigens toward the development of a universal influenza vaccine.

KW - Influenza virus

KW - internal proteins

KW - MVA vector

KW - transgenic mice

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85009275361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009275361&partnerID=8YFLogxK

U2 - 10.1080/20477724.2016.1275465

DO - 10.1080/20477724.2016.1275465

M3 - Article

C2 - 28079473

AN - SCOPUS:85009275361

VL - 111

SP - 76

EP - 82

JO - Pathogens and Global Health

JF - Pathogens and Global Health

SN - 2047-7724

IS - 2

ER -